Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Once-nightly oral pill helps control obstructive sleep apnea

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference.

18 May 2026

Health experts outline symptoms and risks of shipboard hantavirus

It's one of the cruisegoer's biggest fears: a contagious disease outbreak at sea.

18 May 2026

Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.

14 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Study challenges structural explanation for gut symptoms in hEDS patients

A study, led by experts at the University of Nottingham, has found that persistent and distressing upper gut symptoms experienced by people with hypermobile Ehlers-Danlos syndrome (hEDS), are not due to structural problems with the gullet (esophagus), as previously assumed.

13 May 2026

Brain imaging study identifies two distinct biological migraine subtypes

They've been described as "brain on fire" or "an ice pick through the head." Migraine headaches affect more than one in 10 Americans, and they're so much worse than a regular headache.

8 May 2026

GLP-1 drugs may reshape how brain values rewarding foods

A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.

6 May 2026

First European trial tests CAR T therapy in amyloidosis patients

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Millions of Americans with hepatitis C still remain untreated, analysis reveals

Millions of Americans are still battling potentially deadly hepatitis C even though they could be cured with antiviral drugs they are not receiving, a new analysis reveals.

21 Apr 2026

Study identifies new genes linked to severe pregnancy sickness

The USC research team that recently identified the hormone-encoding gene GDF15 as a key driver of pregnancy sickness has identified 9 additional genes linked to its most severe form, hyperemesis gravidarum (HG).

14 Apr 2026

AI analyzes Reddit posts to find underreported GLP-1 side effects

By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.

10 Apr 2026

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

A large 23andMe-based GWAS found that common variants in GLP1R and GIPR help explain why some people lose more weight or experience more nausea and vomiting on GLP-1 drugs. The findings suggest genetics may eventually help predict who responds best to semaglutide or tirzepatide and who is more likely to develop side effects.

9 Apr 2026

Study finds genetic basis for GLP-1 weight loss efficacy and side effects

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects.

8 Apr 2026

New 3D printing method delivers cancer drugs directly to tumors

University of Mississippi research offers hope that cancer drug therapies packaged in 3D-printed carriers could deliver medication directly to tumors while reducing many of the side effects that cancer patients endure.

6 Apr 2026

Parasites trigger a gut-to-brain signal that cuts food intake during infection

Researchers found that intestinal tuft cells signal to crypt enterochromaffin cells by releasing acetylcholine, triggering serotonin release and activating a gut-to-brain vagal pathway during type 2 inflammation. This sustained signalling, rather than the initial acute response, was linked to reduced food intake in mouse models of parasitic infection.

29 Mar 2026